Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week. [Review]

MedStar author(s):
Citation: Journal of the American College of Cardiology. 77(8):1122-1134, 2021 03 02.PMID: 33632487Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Giant Cells/pa [Pathology] | *Myocarditis/th [Therapy] | Algorithms | Biomarkers/bl [Blood] | Biopsy | Cardiovascular Agents/tu [Therapeutic Use] | Defibrillators, Implantable | Electrocardiography | Endocardium/pa [Pathology] | Heart Transplantation | Heart-Assist Devices | Heart/dg [Diagnostic Imaging] | Humans | Immunosuppressive Agents/tu [Therapeutic Use] | Myocarditis/di [Diagnosis] | Natriuretic Peptide, Brain/bl [Blood] | Troponin I/bl [Blood]Year: 2021Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:
  • 0735-1097
Name of journal: Journal of the American College of CardiologyAbstract: Giant cell myocarditis is a rare, often rapidly progressive and potentially fatal, disease due to T-cell lymphocyte-mediated inflammation of the myocardium that typically affects young and middle-aged adults. Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable ventricular arrhythmias, and/or heart block. Diagnosis is often difficult due to its varied clinical presentation and overlap with other cardiovascular conditions. Although cardiac biomarkers and multimodality imaging are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnosis. Combination immunosuppressive therapy, along with guideline-directed medical therapy, has led to a paradigm shift in the management of giant cell myocarditis resulting in an improvement in overall and transplant-free survival. Early diagnosis and prompt management can decrease the risk of transplantation or death, which remain common in patients who present with cardiogenic shock. Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.All authors: Bang V, Barac A, Chaudhry GM, Cooper LT, Dani SS, Ganatra S, Hayek SS, Leja M, Lenihan D, Neilan TG, Nohria A, Parikh R, Patel R, Patten R, Piemonte TC, Resnic FS, Shah SP, Sharma A, Thavendiranathan P, Venesy D, Vesely MOriginally published: Journal of the American College of Cardiology. 77(8):1122-1134, 2021 Mar 02.Fiscal year: FY2021Digital Object Identifier: Date added to catalog: 2021-03-10
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33632487 Available 33632487

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

Giant cell myocarditis is a rare, often rapidly progressive and potentially fatal, disease due to T-cell lymphocyte-mediated inflammation of the myocardium that typically affects young and middle-aged adults. Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable ventricular arrhythmias, and/or heart block. Diagnosis is often difficult due to its varied clinical presentation and overlap with other cardiovascular conditions. Although cardiac biomarkers and multimodality imaging are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnosis. Combination immunosuppressive therapy, along with guideline-directed medical therapy, has led to a paradigm shift in the management of giant cell myocarditis resulting in an improvement in overall and transplant-free survival. Early diagnosis and prompt management can decrease the risk of transplantation or death, which remain common in patients who present with cardiogenic shock. Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

English

Powered by Koha